0000000000745666

AUTHOR

Daniel R. Radiloff

showing 2 related works from this author

Anti-Hypotensive Treatment and Endothelin Blockade Synergistically Antagonize Exercise Fatigue in Rats under Simulated High Altitude

2013

Rapid ascent to high altitude causes illness and fatigue, and there is a demand for effective acute treatments to alleviate such effects. We hypothesized that increased oxygen delivery to the tissue using a combination of a hypertensive agent and an endothelin receptor A antagonist drugs would limit exercise-induced fatigue at simulated high altitude. Our data showed that the combination of 0.1 mg/kg ambrisentan with either 20 mg/kg ephedrine or 10 mg/kg methylphenidate significantly improved exercise duration in rats at simulated altitude of 4,267 m, whereas the individual compounds did not. In normoxic, anesthetized rats, ephedrine alone and in combination with ambrisentan increased heart…

Critical Care and Emergency MedicinePulmonologyPhysiologyAcclimatizationRespiratory Systemlcsh:MedicineAltitude SicknessPharmacologyCardiovascular PhysiologyDrug DiscoveryMedicine and Health SciencesDrug InteractionsSympathomimeticslcsh:ScienceFatigueAltitude sicknessEphedrineMammalsMultidisciplinaryPhenylpropionatesAltitudeDrug SynergismHematologyAnimal ModelsCell HypoxiaPyridazinesmedicine.anatomical_structureVertebratesBlood CirculationDrug Therapy CombinationAnatomymedicine.symptomEndothelin receptorPerfusionInjections IntraperitonealResearch Articlemedicine.drugDrug Research and DevelopmentAmbrisentanEndothelin A Receptor AntagonistsCardiologyEnvironmental and Occupational Lung DiseasesResearch and Analysis MethodsRodentsCardiovascular PharmacologyModel OrganismsHeart ratemedicineAnimalsRespiratory PhysiologySports and Exercise MedicinePharmacologyDose-Response Relationship Drugbusiness.industryAcute Cardiovascular Problemslcsh:ROrganismsHemodynamicsBiology and Life SciencesSkeletal muscleHypoxia (medical)medicine.diseaseRatsDisease Models AnimalBlood pressureMethylphenidateCardiovascular Anatomylcsh:QClinical MedicinebusinessPLoS ONE
researchProduct

The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans.

2017

Hypoxemia can be life-threatening, both acutely and chronically. Because hypoxemia causes vascular dysregulation that further restricts oxygen availability to tissue, it can be pharmacologically addressed. We hypothesized that theophylline can be safely combined with the β2-adrenergic vasodilator bambuterol to improve oxygen availability in hypoxemic patients. Ergogenicity and hemodynamic effects of bambuterol and theophylline were measured in rats under hypobaric and normobaric hypoxia (12% O2). Feasibility in humans was assessed using randomized, double-blind testing of the influence of combined slow-release theophylline (300 mg) and bambuterol (20 mg) on adverse events (AEs), plasma K+,…

AdultMaleCombination therapyPhysiologyAdrenergicBiological Availability030204 cardiovascular system & hematologyPharmacologyHypoxemia03 medical and health sciencesYoung Adult0302 clinical medicineTheophyllinePhysiology (medical)Physical Conditioning AnimalmedicineTerbutalineAnimalsHumansTheophyllineDrug InteractionsBambuterolHypoxiaPharmacologybusiness.industryHemodynamicsGeneral MedicineDrug interactionHypoxia (medical)RatsBlood pressureTreatment OutcomeAnesthesiaFemalemedicine.symptomSafetybusiness030217 neurology & neurosurgerymedicine.drugHalf-LifeCanadian journal of physiology and pharmacology
researchProduct